Please select the option that best describes you:
Do you routinely use a bone modifying agent in patients with metastatic RCC with bone metastases receiving a TKI?
Would you avoid combination with TKI given possible higher risk of osteonecrosis of the jaw?
Answer from: Medical Oncologist at Academic Institution
Agree. For the most part, I don’t use BMA to treat bone mets as there is a lack of data/representation of RCC patients in BMA studies in solid tumors. With that said, I’ve discussed it in selected cases with disseminated bone mets. Differently, I do offer BMA to treat osteoporosis/osteop...
Sign in or Register to read more